

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 March 2024 (07.03.2024)



(10) International Publication Number
WO 2024/047574 A1

(51) International Patent Classification:

A61K 31/538 (2006.01) A61K 9/48 (2006.01)
A61K 31/70 (2006.01) A61P 9/04 (2006.01)
A61K 9/16 (2006.01) A61P 13/12 (2006.01)

(21) International Application Number:

PCT/IB2023/058617

(22) International Filing Date:

31 August 2023 (31.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/374,257 01 September 2022 (01.09.2022) US
63/520,952 22 August 2023 (22.08.2023) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151-85, Södertälje (SE).

(72) Inventors: **KARLSSON, Eva**; ASTRAZENECA AB, SE-151-85 Södertälje (SE). **KARLSSON, Christer**; ASTRAZENECA AB, SE-151-85 Södertälje (SE). **HJÄRTS-TAM, Johan**; ASTRAZENECA AB, SE-151-85 Södertälje (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERT**; Eastbrook House, Shaftesbury Road, Cambridge Cambridgeshire CB2 8BF 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: COMBINATION OF SGLT2 INHIBITORS AND MINERALCORTICOID RECEPTOR MODULATORS FOR USE IN TREATMENT OF CARDIORENAL DISEASES




FIG. 2A

(57) Abstract: A pharmaceutical composition comprising: (a) one or more of a first pellet comprising i. a first core, and ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator and a first binder; and (b) one or more of a second pellet comprising i. a second core, and ii. a second coating on the second core, wherein the second coating comprises an SGLT2 inhibitor, wherein the SGLT2 inhibitor is about 5% to about 20% by weight of the second pellet, wherein the composition comprises about 20% to about 50% by weight of the mineralocorticoid receptor (MR) modulator; and about 1% to about 10% by weight of the SGLT2 inhibitor. Said compositions for use in the treatment of chronic kidney disease or heart failure.

WO 2024/047574 A1